Summary
Highly purified pork monocomponent insulin produced less anti-insulin antibody than conventional insulins in diabetic patients. The smaller amount of anti-insulin antibody produced by MC insulin bound pork insulin more strongly than beef insulin in both displacement and direct binding studies of125I-insulin. On the contrary, anti-insulin antibody which was produced by conventional insulins (beef insulin or mixture of pork and beef insulin) bound beef insulin more strongly. No significant anti-a-component and anti-proinsulin antibodies were detected in diabetics treated with highly purified monocomponent pork insulin about two years, compared to significant production of these antibodies in diabetics treated with conventional insulins. These results suggest that the species difference of the insulin molecule itself plays a significant role for the production of anti-insulin antibody, as the impurities do, in insulin-treated diabetic patients. The production of anti-insulin and anti-a-component antibodies decreased clearly after switching to highly purified monocomponent from conventional insulin. No effect of the switching on insulin requirement was found; however, better control of diabetes was accomplished in relation to the level of fasting blood sugar.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andreani D., Iavicoli M., Tamburrano G., Menzinger G.: Comparative trials with mono-component (MC) and monospecies (MS) pork insulins in the treatment of diabetes mellitus. Influence on antibody levels, on insulin requirement and on some complications — Hormone metab. Res.6, 447, 1974.
Asplin C. M., Hartog M., Goldie D. J.: Change of insulin dosage, circulating free and bound insulin and insulin antibodies on transferring diabetics from conventional to highly purified porcine insulin — Diabetologia14, 99, 1978.
Banting F. G., Frank W. R., Gairns S.: Anti-insulin activity of serum of insulin treated patients — Amer. J. Psychiat.95, 562, 1938.
Berson S. A., Yalow R. S.: Quantitative aspects of the reaction between insulin and insulin-binding antibody — J. clin. Invest.38, 1996, 1959.
Bruni B., D’Alberto M., Osenda M., Ricci C., Turco G. L.: Clinical trial with mono-component lente insulins. Preliminary report — Diabetologia9, 492, 1973.
Bruni B., Gamba S., Regis G., Turco G. L.: Proinsulin and a-component antibodies in diabetics after long-term monocomponent insulin treatment — Diabetologia14, 165, 1978.
Czyżyk A., Ławecki J., Rogala H., Miedzińska E., Popik-Hankiewicz A.: Serum levels of insulin-binding antibodies in diabetic patients treated with monocomponent insulin — Diabetologia10, 233, 1974.
Desbuquois B., Aurvach G. D.: Use of polyethylene glycol to separate free and antibodybound peptide hormones in radioimmunoassays — J. clin. Endocr.33, 732, 1971.
Grodsky G. M.: Production of auto-antibodies to insulin in man and rabbits — Diabetes14, 396, 1965.
Hunter W. M., Greenwood J. C.: Preparation of iodine-131 labeled human growth hormone of high specific activity — Nature (Lond.)194, 495, 1962.
Kawazu S., Kanazawa Y., Kajinuma H., Miki E., Kuzuya T., Kosaka K.: Demonstration of anti-‘a-component’ antibody — A possible means to differentiate patients with auto-antibodies to endogenous insulin from insulin-treated patients — Diabetologia11, 169, 1975.
Korp W., Levett R. E.: Erfahrungen mit Monokomponenten-Insulin — Wien. klin. Wschr.18, 326, 1963.
Kumar D., Mehtalia S. D., Miller L. V.: Antigenicity of monocomponent porcine insulin in rabbits — Hormone metab. Res.6, 175, 1974.
Levett R. E., Korp W.: A clinical trial with monocomponent (MC)-insulin. Preliminary results — Diabetologia8, 55, 1972.
Little J. A., Lee R., Sebriakova M., Csima A.: Insulin antibodies and clinical complications in diabetics treated for five years with lente or sulfated insulin — Diabetes26, 980, 1977.
Neubauer H. P., Schöne H. H.: The immunogenicity of different insulins in several animal species — Diabetes27, 8, 1978.
Renold A. E., Steinke J., Soeldner J. S., Antoniades H. N., Smith R. L.: Immunological response to the prolonged administration of heterologous and homologous insulin in cattle — J. clin. Invest.45, 702, 1966.
Schlichtkrull J.: Monocomponent insulin and its clinical implications — Hormone metab. Res.5 (Suppl. 5), 134, 1974.
Schlichtkrull J., Brange J., Christiansen Aa. H., Hallund O., Heding L. G., Jørgensen K. H.: Clinical aspects of insulin-antigenicity — Diabetes21 (Suppl. 2), 649, 1972.
Schlichtkrull J., Brange J., Heding L. G., Christiansen Aa. H., Jørgensen K. H., Sorensen E., Vølund Aa.: Antibodies to components of insulin — Lecture held at the Royal Society of Medicine’s Meeting, London 1974.
Sebriakova M., Little J. A.: A method for the determination of plasma insulin antibodies and its application in normal and diabetic subjects — Diabetes22, 30, 1973.
Siegel S.: Nonparametric statistics for the behavioral sciences — International Student Edition, McGraw-Hill Kogakusha Ltd., Tokyo, 1959; p. 75.
Tuft L.: Insulin hypersensitiveness. Immunologic considerations and case reports — Amer. J. med. Sci.176, 707, 1928.
Yue D. K., Turtle J. T.: Antigenicity of ‘monocomponent’ pork insulin in diabetic subjects — Diabetes24, 625, 1975.
Yue D. K., Turtle J. T.: New forms of insulin and their use in the treatment of diabetes — Diabetes26, 341, 1977.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kawazu, S., Kanazawa, Y., Miki, E. et al. The production and characteristics of anti-insulin, anti-a-component and anti-proinsulin antibodies in patients treated with monocomponent or conventional insulin. Acta diabet. lat 16, 339–351 (1979). https://doi.org/10.1007/BF02587655
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02587655